Validation and refinement of survival models for liver retransplantation

Hepatology

Volumn 38, Issue 2, 2003, Pages 460-469

  Rosen, Hugo R ^a,h   Prieto, Martin ^b   Casanovas Taltavull, Teresa ^c   Cuervas Mons, Valentin ^d   Guckelberger, Olaf ^e   Muiesan, Paolo ^f   Strong, Russell W ⁱ   Bechstein, Wolf O ^e   O'Grady, John ^f   Zaman, Atif ^a   Chan, Benjamin ^a   Berenguer, Joaquin ^b   Williams, Roger ^g   Heaton, Nigel ^f   Neuhaus, Peter ^e  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h PORTLAND VA MEDICAL CENTER   (United States)

ⁱ NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AREA UNDER THE CURVE; ARTICLE; COHORT ANALYSIS; FEMALE; HUMAN; INTERNATIONAL STANDARD UNIT; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTHROMBIN TIME; REGISTER; SCORING SYSTEM; SURVIVAL RATE; VALIDATION PROCESS;

EID: 0042766826     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2003.50328     Document Type: Article

References (29)

1. www.Unos.org. Accessed: June 1, 2001.
2. Keeffe EB. Liver transplantation: current status and novel approaches to liver replacement. Gastroenterology 2001;120:749-762.
3. Rosen HR. Disease recurrence following liver transplantation. Clin Liver Dis 2000;4:675-689.
4. Biggins SW, Beldecos A, Rabkin JM, Rosen HR. Retransplantation for hepatic allograft failure: prognostic modeling and ethical considerations. Liver Transpl 2002;8:313-322.
5. Wall WJ. Recurrent disease after liver transplantation, implications for the future. Liver Transplant Surg 1997;6:362-367.
6. Rosen HR, Madden JP, Martin P. A model to predict survival following hepatic retransplantation. HEPATOLOGY 1999;29:365-370.
7. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D'Amico G, et al. A model to predict survival in patients with end-stage liver disease. HEPATOLOGY 2001;33:464-470.
8. Cox DR. Regression models and life-tables. J R Stat [B] 1972;34:187-202.
9. Dickson ER, Murtaugh PA, Wiesner RH, Grambsch PM, Fleming TR, Ludwig J, La Russo NF, et al. Primary sclerosing cholangitis: refinement and validation of survival models. Gastroenterology 1992;103:1893-1901.
10. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36.
11. Berenguer M, Prieto M, Palau A, Rayon JM, Carraasco D, Juan SJ, Lopez-Labrado FX, et al. Severe recurrent hepatitis C after liver retransplantation for hepatitis C virus-related graft cirrhosis. Liver Transpl 2003;9:228-235.
12. Brown RS Jr, Kumar KS, Russo MW, Kinkhabwala M, Rudow DL, Harren P, Lobritto S, et al. Model for end-stage liver disease and Child-Turcotte-Pugh score as predictors of pretransplantation disease severity, posttransplantation outcome, and resource utilization in United Network for Organ Sharing status 2A patients. Liver Transpl 2002;8:278-284.
13. Onaca NN, Levy MF, Sanchez EQ, Chinnakotla S, Fasola CG, Thomas MJ, Weinstein JS, et al. A correlation between pretransplantation MELD score and mortality in the first two years after liver transplantation [Comments]. Liver Transpl 2003;9:117-123.
14. Forman LM, Lucey MR. Predicting the prognosis of chronic liver disease: an evolution from child to MELD. HEPATOLOGY 2001;33:473-475.
15. Neil DAH, Hubscher SG. Histologic and biochemical changes during the evolution of chronic rejection of liver allografts. HEPATOLOGY 2002;35:639-651.
16. Reuss ML, Paneth N, Pinto-Martin JA, Lorenz JM, Susser M. The relation of transient hypothyroxinemia in preterm infants to neurologic development at two years of age. N Engl J Med 1996;334:821-827.
17. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, Cordoba J, et al. HCV-relared fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000;32:673-684.
18. Berenguer M, Prieto M, Rayon JM, Mora J, Pastor M, Ortiz V, Carrasco D, et al. Natural history of clinically compensated hepatitis C virus-related graft cirhosis after liver transplantation. HEPATOLOGY 2000;32:852-858.
19. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens F, et al. Morrbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-472.
20. Kim WR, Wiesner RH, Poterrucha JJ, Therneau TM, Malinchoc M, Benson JT, Crippin JS, et al. Hepatic retransplantation in cholestatic liver disease: impact of the interval to retransplantation on survival and resource utilization. HEPATOLOGY 1999;30:395-400.
21. Wong T, Devlin J, Rolando N, Heaton N, Williams R. Clinical characteristics affecting the outcomes of liver retransplantation. Transplantation 1997;4:878-882.
22. Doyle HR, Morelli F, McMichael J, Doria C, Aldrighetti L, Starzl TE, Marino IR. Hepatic retransplantation: an analysis of risk factors associated with outcome. Transplantation 1996;61:1499-1505.
23. Markman JF, Gornbein J, Morkowitz JS, Levy MF, Klintmalm GB, Yersiz H, Morrisey M, et al. A simple model to estimate survival after retransplantation of liver. Transplantation 1999;647:422-430.
24. Azoulay D, Linhares MM, Huguet E, Delvart V, Castain D, Adam R, Ichai P, et al. Decision for retransplantation of the liver: an experience- and cost-based analysis. Ann Surg 2002;236:713-721.
25. Adam R, Cailliez V, Manjo P, Karam V, McMaster P, Calne RY, O'Grady J, et al. Normalized intrinsic mortality risk in liver transplantation: European Liver Transplant Registry study. Lancet 2000;356:621-627.
26. Everson G. MELD: the answer or just more questions? Gastroenterology 2003;124:251-254.
27. Ubel PA, Arnold RM, Caplan AL. Rationing failure: the ethical lessons of the retransplantation of scarce vital organs. JAMA 1993;270:2469-2474.
28. Evans RW, Manninen DL, Dong FB, McLynne DA. Is retransplantation cost effective? Transplant Proc 1993;25:1694-1697.
29. Roberts JP. Prioritization of patients with liver cancer within the MELD system. Liver Transpl 2002;9:329-330.